Strongbridge Biopharma plc presents detailed results of the RECORLEV® phase 3 LOGIC study (levocetoconazole) for the treatment of endogenous Cushing’s syndrome at the Endocrine Society’s 2021 annual meeting (ENDO)
Colorado is expected to adjust dialing again next week, ending personal meeting limits and easing restrictions
